Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-469/coif). DA reports receiving consulting fees from Genentech, Exelixis, Eisai, Advanced Accelerator Applications, and Astra Zeneca. TBS reports research funding to his institution from Arys, Arcus, Atreca, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer and BMS; consulting fee to his institution from Ipsen, Arcus, Array Biopharma, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte and Merck; consulting fee to himself from Stemline, AbbVie and Boehringer Ingelheim Janssen, Eisai, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, Sobi, Beigene, Kanaph, Xilis, Astra Zeneca and Foundation Medicine; participation on Data Safety Monitoring Board in Fibrogen, Suzhou Kintor, Astra Zeneca, Exelixis, Lilly, PanCan and 1Globe; participation on Scientific Advisory Board in Imugene, Immuneering and Sun Biopharma; patents of WO/2018/183488 and WO/2019/055687. The authors have no other conflicts of interest to declare.